Objective. The goal of this study was to determine the maximal tolerated dose (MTD) of topotecan given with external-beam radiotherapy in advanced cervical cancer. Methods. A prospective Phase I trial of topotecan given with standard external-beam radiotherapy was performed in patients with advanced squamous cell carcinoma of the cervix. Patients were treated with a starting dose of 0.5 mg/m2 and escalated by 0.25 mg/m2. Nine patients were treated. Hematologic and nonhematologic toxicity were measured. Results. Patients were treated with 1.0 mg/m2 daily for 5 days on Days 1-5 and 22-26 concomitantly with radiotherapy without significant toxicity. Grade III anemia in one case and Grade II leukopenia in two cases were seen in the three patients at this dose level. Dose-limiting toxicity was not reached. Conclusion. Topotecan can be safely administered at a dose of 1.0 mg/m2 during external-beam radiotherapy for advanced cervical cancer.
|Original language||English (US)|
|Number of pages||3|
|State||Published - 2002|
- Radiation sensitization
- Squamous cell carcinoma of the cervix
ASJC Scopus subject areas
- Obstetrics and Gynecology